Expression of tetraspanin 1 in breast cancer and its mechanism in promoting the progression of breast cancer

doi:10.3969/j.issn.1674-8115.2023.03.004

Abstract

Abstract:

Objective ·To investigate the expression of tetraspanin 1 (TSPAN1) in breast cancer and its effect on the migration and invasion of breast cancer cells. Methods ·Immunohistochemistry staining (IHC) was used to detect the expression of TSPAN1 in breast cancer tissues and para-tumor tissues from 106 clinical patients, and to analyze its correlation with the clinical characteristics of patients. The Cancer Genome Atlas (TCGA) database was used to analyze the expression of TSPAN1 mRNA in breast cancer tissues and para-tumor tissues, and its correlation with the clinical characteristics of patients. After down-regulation of TSPAN1 in breast cancer cells MDA-MB-231 and SUM159PT, the effects of TSPAN1 on migration and invasion of cells were detected by wound healing assay and transwell assay, and the expression of epithelial-mesenchymal transition (EMT)-related proteins (E-cadherin, N-cadherin and vimentin) were detected by Western blotting. Results ·IHC results showed that the expression of TSPAN1 in breast cancer tissues was higher than that in para-tumor tissues (P=0.000), and the expression of TSPAN1 in total TNM stages, M stages, N stages and pathological grades of breast cancer tissues showed statistically significant differences (all P<0.05). The results of transcriptome sequencing data from TCGA database showed that the expression of TSPAN1 mRNA in breast cancer tissues was higher than that in para-tumor tissues (P=0.000), and its expression in TNM Ⅲ?Ⅳ stages was higher than that in TNMⅠ?Ⅱ stages (P=0.007). After down-regulation of TSPAN1, the migration and invasion ability of MDA-MB-231 and SUM159PT cells were decreased, the expression of E-cadherin was increased and the expressions of N-cadherin and vimentin were decreased (all P<0.05). Conclusion ·TSPAN1 is highly expressed in breast cancer tissues, which can promote the migration and invasion of breast cancer cells.

Key words: breast cancer, tetraspanin 1 (TSPAN1), epithelial-mesenchymal transition (EMT)

CLC Number:

R737.9

CAO Yuan, WANG Hongxia, ZHU Ying, LI Junjian. Expression of tetraspanin 1 in breast cancer and its mechanism in promoting the progression of breast cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(3): 293-300.

Figures/Tables 5

Tab 1 Sequences of siRNA

siRNA	Forward (5′→3′)	Reverse (5′→3′)
Control siRNA	UUCUCCGAACGUGUCACGUTT	ACGUGACACGUUCGGAGAATT
TSPAN1 siRNA 1	CGUUUCGUCAAAGAGAAUATT	UAUUCUCUUUGACGAAACGTT
TSPAN1 siRNA 2	GGCUCACGACCAAAAAGUATT	UACUUUUUGGUCGUGAGCCTT

Fig 1 Expression of TSPAN1 in breast cancer tissues and para-tumor tissues and its relationship with clinical characteristics of patients

Fig 2 Expression of TSPAN1 mRNA in breast cancer tissues and para-tumor tissues and its correlation with patients' clinical characteristics in TCGA database

Fig 3 Effects of silencing TSPAN1 on the migration and invasion ability of MDA-MB-231 and SUM159PT cells

Fig 4 Detection of EMT-related proteins expression in MDA-MB-231 and SUM159PT cells after silencing TSPAN1

TrendMD

References 15

1	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29.
2	STEEG P S. Targeting metastasis[J]. Nat Rev Cancer, 2016, 16(4): 201-218.
3	ZHU R X, GIRES O, ZHU L Q, et al. TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling[J]. Nat Commun, 2019, 10(1): 2863.
4	HUANG Y W, LI J J, DU W Q, et al. Nuclear translocation of the 4-pass transmembrane protein Tspan8[J]. Cell Res, 2021, 31(11): 1218-1221.
5	LU X Q, AN L W, FAN G J, et al. EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription[J]. Cell Res, 2022, 32(4): 359-374.
6	HEMLER M E. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain[J]. Annu Rev Cell Dev Biol, 2003, 19: 397-422.
7	CHEN L, YUAN D Y, WANG G L, et al. Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma[J]. J Korean Med Sci, 2010, 25(10): 1438-1442.
8	WANG S S, LIU X H, KHAN A A, et al. miR-216a-mediated upregulation of TSPAN1 contributes to pancreatic cancer progression via transcriptional regulation of ITGA2[J]. Am J Cancer Res, 2020, 10(4): 1115-1129.
9	CHEN L, ZHU Y Y, ZHANG X J, et al. TSPAN1 protein expression: a significant prognostic indicator for patients with colorectal adenocarcinoma[J]. World J Gastroenterol, 2009, 15(18): 2270-2276.
10	SCHOLZ C J, KURZEDER C, KORETZ K, et al. Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas[J]. Cancer Lett, 2009, 275(2): 198-203.
11	WU Y G, CHEN W X, GONG Y F, et al. Tetraspanin 1 (TSPAN1) promotes growth and transferation of breast cancer cells via mediating PI3K/Akt pathway[J]. Bioengineered, 2021, 12(2): 10761-10770.
12	MENKE C H, POHLMANN P R, BACKES A, et al. Tumor size as a surrogate end point for the detection of early breast cancer: a 30-year (1972‒2002), single-center experience in southern Brazil[J]. Breast J, 2007, 13(5): 448-456.
13	LOIBL S, POORTMANS P, MORROW M, et al. Breast cancer[J]. Lancet, 2021, 397(10286): 1750-1769.
14	ESTEVA F J, HUBBARD-LUCEY V M, TANG J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer[J]. Lancet Oncol, 2019, 20(3): e175-e186.
15	LI J J, CHEN X L, ZHU L Q, et al. SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer[J]. Oncogene, 2021, 40(30): 4884-4893.

[1]	YANG Xiaoxuan, ZHU Shan, QIAN Cheng, CHU Xiaoying. Effect of intraoperative use of low-dose dexmedetomidine on the prognosis of patients undergoing breast cancer surgery [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 194-200.
[2]	XIA Kunjian, DENG Linlin, WANG Lin. Construction and evaluation of a prediction model for liver injury induced by chemotherapy for breast cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(4): 502-509.
[3]	ZHANG Yutang, JIN Yijie, ZHANG Fengchun, XU Yingchun. Exploration on rationalization of diagnosis and treatment of breast cancer patients combined with COVID-19 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(12): 1745-1750.
[4]	SU Juncheng, WANG Yuzheng, TANG Lei, XU Yingchun, ZHANG Fengchun. Clinical and pathological characteristics as well as prognostic analysis of breast cancer patients with brain metastases [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1562-1568.
[5]	SUN Yameng, MA Ye, GUO Runsheng. Detection and analysis of copy number of HER2 gene in breast cancer tissue samples [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(11): 1589-1597.
[6]	WANG Yuzheng, SU Juncheng, TANG Lei, XU Yingchun, ZHANG Fengchun. Weekly paclitaxel in combination with cisplatin in the first-line treatment of metastatic breast cancer: a retrospective study [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(10): 1420-1427.
[7]	Cui CHEN, Ye JIN, Lin WANG, Hongli LI, Caifeng WAN, Lixin JIANG. Comparative analysis of 30 cases of metaplastic carcinoma of the breast [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2022, 42(1): 70-76.
[8]	Bing-qian ZHOU, Li HAN, Zhe-yi CHEN, Shi-yu CHEN, Ying-xia ZHENG. Expression of protein arginine methyltransferase 5 in lung cancer and its mechanism of promoting lung cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1009-1016.
[9]	Tian-hao ZHOU, Zhao-chen XIN, Shao-qian DU, Yuan CAO, Jing-xuan XU, Zeng-hong LAO, Hong-xia WANG. Establishment and optimization of co-culture technology for breast cancer organoids [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1017-1024.
[10]	Yan-jie JI, Hao LUO, Hai-yan CAI, Xin-yu LIU, Shi-jia JIN, Shen-yue SU, Han-zhang XU, Hu LEI, Ying-li WU. Inhibition of CDDO-ME on ubiquitin-specific protease 2a activity and cell proliferation in triple negative breast cancer cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1025-1032.
[11]	Cheng-zhi WANG, Hua-yun DENG, Zhi PANG, Lei HUANG. Mechanism of MUC1 in the pathogenesis of HER2-positive breast cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 839-848.
[12]	Jia-ling ZHANG, Feng-chun ZHANG, Ying-chun XU. Research progress in the systemic treatment for breast cancer with brain metastasis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 671-677.
[13]	Yan-yun HAO, Si-hui YÜ, Jing LU, Xiang GU, Fan ZHANG, Jin-ke CHENG, Tian-shi WANG. Role of SIRT3 SUMOylation deficiency in the proliferation and chemotherapeutic sensitivity of breast cancer cells MCF7 [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1557-1563.
[14]	Lu GAN, Yu-fei JIN, Qing REN, Xiao-jing DONG, Nan ZHANG. Experience of sexuality after breast reconstruction in breast cancer survivors: a qualitative study [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1597-1601.
[15]	Ye-zi CHAI, Jun MA, Wen-long JIANG, Qi-ming LIU, Qi-fan LU, Zheng-yu TAO, Meng JIANG, Jun PU. Assessment of cardiopulmonary exercise capacity in early stage of patients with breast cancer undergoing neoadjuvant chemotherapy and related factors [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1643-1648.